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Kinase inhibitors have ushered in the era of targeted therapy, but their utility to date is primarily 
limited to cancers bearing oncogenic kinase mutations. Two papers in this issue (Luo et al., 2009; 
Scholl et al., 2009) could change this landscape by uncovering kinase-specific vulnerabilities in 
tumors with RAS mutations.The success of kinase inhibitors in treat-
ing cancers bearing mutations in kinases 
has fueled a growing transformation of 
the cancer drug development enterprise 
into one informed by cancer genom-
ics. The new mantra, quite simply, is 
that cancers bearing oncogenic muta-
tions in a kinase are dependent on that 
kinase for growth and survival. With rare 
exception, patients with such tumors 
have derived significant benefit (that is, 
their tumors shrink) when treated with an 
inhibitor of that mutant kinase. The prob-
ability of success in such patients is so 
high that drug discovery programs can 
(and should) be launched when a new 
kinase mutation is discovered in a sub-
set of human cancers. The drugs that 
emerge are anticipated to be active as 
single agents when studied in appropri-
ate patients and can rapidly advance 
through clinical development. Yet, this 
may not be the only promising approach 
to discover new therapeutic targets. In 
this issue, Luo et al. (2009) and Scholl 
et al. (2009) report the use of large-scale 
RNA interference screens to probe the 
vulnerabilities of cancer cells expressing 
oncogenic K-RAS.
The confidence born of the success 
with kinase inhibitors provides much 
of the rationale for the Cancer Genome 
Atlas, the national effort to resequence 
the genomes of several hundred tumors 
of each major human cancer (Cancer 
Genome Atlas Research Network, 2008). 
Of course, this encyclopedic approach 
is costly and may yield few new leads. 
At least one new mutant (and presum-
ably druggable) cancer target, isoci-796 Cell 137, May 29, 2009 ©2009 Elsevier Intrate dehydrogenase 1 gene (IDH1), has 
emerged from an independent glioblas-
toma resequencing project (Parsons et 
al., 2008). However, its utility as a drug 
target remains unclear, given recent evi-c.dence suggesting that mutant IDH1 has 
a tumor suppressor rather than an onco-
genic function (Yan et al., 2009).
The Cancer Genome Atlas also has 
the broader goal of generating a com-Figure 1. shRNA Screening Strategies: Well-by-Well versus Pooled Libraries
(A) In the well-by-well approach, the impact of each individual short hairpin RNA (shRNA) on growth 
or survival is scored after a predefined incubation period. shRNAs that selectively kill cells bearing the 
mutant oncogene versus wild-type cells (designated by “X”) are deemed “hits.” Genes targeted across 
a panel of mutant cell lines and by independent hairpins rank highest on the hit list. The well-by-well ap-
proach requires a high-throughput screening infrastructure due to the number of shRNAs in a reasonably 
comprehensive library and the number of cell lines screened to generate confidence in hits.
(B) With the pooled screening approach, cells are infected with the entire pooled shRNA library at a low 
multiplicity of infection (to assure one shRNA per cell. The cells are then passaged for multiple population 
doublings to deplete those cells whose growth is adversely impacted by a specific shRNA. The identity of 
shRNAs that drop out during serial passage (designated by “X”) is determined by barcode array hybridization. 
As with the well-by-well approach, genes targeted by more than one independent shRNAs in multiple cell lines 
are ranked most highly. Both strategies are limited by an unknown but presumably high “false negative” rate, 
given that few of the shRNAs in current libraries are validated to confer substantial knockdown.
plete map of all genomic alterations in 
human cancer. But with rare exceptions, 
such as IDH1, few discoveries are antici-
pated to generate immediately action-
able drug targets. For common but cur-
rently undruggable cancer mutations in 
oncogenes, such as RAS, and tumor 
suppressors, such as PTEN and TP53, 
the Cancer Genome Atlas may provide 
little translational insight.
One alternative is to screen for synthetic 
lethality to identify druggable targets 
that are uniquely required by tumor cells 
but not normal cells (Kaelin, 2005). Two 
general strategies can be envisioned: (1) 
chemical screens in which compounds 
are found that specifically kill tumor 
cells, but these “hits” generally require 
extensive additional work to define their 
protein targets, and (2) RNA interference 
screens in which “hits” immediately 
define a new drug target that, in some 
cases, can be aggressively pursued with 
conventional enzyme-based drug dis-
covery approaches. Pilot studies using 
both strategies have been reported, but 
none of the discoveries from these early 
screens are known to have progressed to 
drug development programs. Therefore, 
in contrast to the impressive track record 
of targets emerging from studies of the 
human cancer oncogenome, the prob-
ability of clinical success with targets 
emerging from synthetic lethal screens 
is unknown. Based on two papers in 
the current issue of Cell, we may get an 
answer soon.
The two independent teams, led 
by Gilliland and Elledge respectively, 
identify two kinases—STK33 (serine/
threonine kinase 33) and PLK1 (polo-
like kinase 1)—in screens for synthetic 
lethality using short hairpin RNAs (shR-
NAs) in human cancer cells expressing 
mutant K-RAS (Scholl et al., 2009; Luo et 
al., 2009). The translational implications 
of both reports are important and imme-
diate. K-RAS is among the most com-
monly mutated human cancer genes, 
and inhibitors of STK33 and PLK1 should 
be relatively straightforward to iden-
tify via standard chemical approaches. 
Indeed, preclinical PLK1 inhibitors have 
already been described (McInnes et al., 
2005; Steegmaier et al., 2007). Clinical 
trials of such inhibitors in patients with 
K-RAS mutant tumors could, in principle, 
begin in 1–2 years.There are important technical differ-
ences between the screens conducted 
by the two groups that may impact the 
broader application of shRNA screening by 
the cancer research community (Figure 1). 
Gilliland and colleagues screened ?5000 
shRNAs targeting ?1000 genes across a 
panel of eight human cancer cell lines (4 
K-RAS wild-type and 4 K-RAS mutant) 
using a well-by-well approach in which the 
biological effects of each hairpin are scored 
individually (Scholl et al. 2009). Annotation 
of “hits” that score only across the four 
K-RAS mutant lines yields a small list of 
genes that include K-RAS (as expected) 
and STK33 at the top. Additional studies in 
several diverse biological systems confirm 
the synthetic lethal association of STK33 
with K-RAS, which, remarkably, appears 
to be specific for K-RAS and does not 
extend to H-RAS or N-RAS mutant tumor 
lines. Furthermore, a few cell lines not pre-
viously known to bear K-RAS mutations 
score as STK33-dependent and are found 
upon closer inspection to bear previously 
unappreciated K-RAS mutations at atypi-
cal codons. Although clearly powerful, 
such large-scale well-by-well screening (at 
least 160,000 wells for a screen limited to 
1000 genes run in quadruplicate) requires 
a high-throughput platform run by spe-
cialized personnel. Cost will preclude the 
academic community from easily expand-
ing this approach to other undruggable 
cancer mutations as well as scaling it for 
whole genome screens.
In contrast, Elledge and colleagues 
use a pooled screening approach 
whereby a library of ?75,000 shRNAs 
targeting ?30,000 mRNA transcripts 
from ?12,000 genes is introduced into a 
K-RAS mutant cancer cell line as well as 
an isogenic wild-type KRAS control (Luo 
et al., 2009). shRNAs targeting ?400 
genes are selectively depleted from the 
library (as detected by barcode arrays) in 
K-RAS mutant cells after multiple popu-
lation doublings and deemed candidate 
RAS synthetic lethals. Roughly a quarter 
of these “hits” were validated in a repeat 
screen, and a subset of these were then 
confirmed in another K-RAS mutant 
isogenic cell line pair, resulting in a list of 
77 validated RAS synthetic lethal genes. 
Perhaps due to the greater scale (whole 
genome) relative to the Gilliland screen, 
no single “hit” emerges as an obvious top 
candidate. Rather, computational analy-Celsis of all “hits” reveals increased depen-
dence of K-RAS mutant cells on the 
mitotic machinery (including the kinase 
PLK1) and the proteasome. As predicted 
from the shRNA analysis, K-RAS mutant 
cells are preferentially killed by clinical 
drugs, such as paclitaxel, which target 
mitotic spindle function, and a preclinical 
PLK1 inhibitor as well as by the protea-
some inhibitor bortezomib.
In addition to the translational impli-
cations for patients with K-RAS mutant 
cancers, these reports will spawn a 
series of investigations by RAS aficio-
nados into why K-RAS mutant cells are 
dependent on STK33, PLK1, and the long 
list of other RAS synthetic lethal genes. 
Curiously, STK33 does not appear to be 
a component of the RAS signaling path-
way and does not, on its own, score as an 
oncogene in transformation assays. Fur-
thermore, there is no evidence of STK33 
mutation or gene amplification in a limited 
analysis of human cancers. Rather, cells 
with mutant K-RAS appear to be rewired 
and, through that process, acquire 
unique dependence on STK33. It will be 
important to dissect the temporal and 
biochemical details of this rewiring, as 
well as the normal function of STK33. The 
enhanced dependence of K-RAS mutant 
cells on basic cellular functions such as 
the mitotic machinery and on the protea-
some is consistent with growing evidence 
that cancer cells are stressed and must 
adapt to avoid stress-induced death that 
typically occurs in normal cells. Indeed, 
much recent work has established that 
some cancer cells are poised to die but 
are rescued by hyperexpression of pro-
survival proteins and that this vulnerabil-
ity can be exploited clinically with Bcl-2 
antagonists such as ABT-737 (Cragg et 
al., 2009; Letai, 2008).
The ultimate validation of the synthetic 
lethal screening strategies outlined here 
will be evidence that patients with K-RAS 
mutant tumors benefit from treatment 
with STK33 or PLK1 inhibitors. Unfor-
tunately we won’t have the answer for 
many years. We already know that a few 
limited but dramatic clinical successes 
with kinase inhibitors helped launch 
a large scale assault on the cancer 
genome to define all cancer mutations. 
How long do we wait before launching 
a similar assault to define all cancer cell 
vulnerabilities?l 137, May 29, 2009 ©2009 Elsevier Inc. 797
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When animal cells divide, one cell is 
cleaved into two by the constriction of 
a cortical ring (Rappaport, 1996). The 
ring is made of actin, myosin II, and 
actin-binding proteins, but the pre-
cise mechanism by which it assembles 
and constricts is still not understood. 
In the prevalent model for constriction 
(sometimes called “pure string con-
traction”), the force for constriction is 
generated by myosin II motors sliding 
actin filaments against each other par-
allel to the cell membrane, contracting 
the diameter of the ring (Schroeder, 
1975). However, this view has been 
questioned and alternative arrange-
ments of actin and myosin II have been 
proposed (Eggert et al., 2006). It has 
even been suggested that constric-
tion force could be generated by actin 
depolymerization rather than myosin II 
activity (Zumdieck et al., 2007). In this 
issue of Cell, Carvalho et al. (2009) 
investigate the rate of ring constriction 
(the change of ring diameter over time) 
during early development of the worm 
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Caenorhabditis elegans, shedding new 
light on the mechanism of cytokinesis 
and its scalability with cell size.
Cortical ring constriction rate in a 
dividing C. elegans embryonic cell is ini-
tially constant but decreases once the 
ring comes in proximity to the midbody, 
a microtubule-based structure that is 
formed between the separated chro-
mosomes in the dividing cell. When for-
mation of the midbody is inhibited, ring 
constriction continues at a constant rate 
until complete closure. This suggests 
that a constant rate of constriction is the 
default behavior that is modified by the 
midbody. 
When early embryos undergo cell divi-
sion, their cells become progressively 
smaller. This provides researchers with 
an opportunity to investigate physical 
scaling relationships (Wühr et al., 2008), 
as it is likely that the biochemistry of the 
embryo (such as protein levels and modi-
fications) remains relatively constant dur-
ing early embryogenesis. Carvalho et al. 
now measure the rate of cytokinesis con-
 Go Hand in Ha
d Christine M. Field1,*
dical School, Boston, MA 02115, USA
rd.edu
diated by the constriction of a cor
f the worm Caenorhabditis elegan
rtional to the initial cell perimete
ent.Barbie, D.A., Kim, S.Y., Silver, S.J., Tamayo, P., 
Wadlow, R.C., Ramaswamy, S., et al. (2009). Cell, 
this issue.
Steegmaier, M., Hoffmann, M., Baum, A., Lenart, 
P., Petronczki, M., Krssak, M., Gurtler, U., Garin-
Chesa, P., Lieb, S., Quant, J., et al. (2007). Curr. 
Biol. 17, 316–322.
Yan, H., Parsons, D.W., Jin, G., McLendon, R., 
Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, 
I., Jones, S., Riggins, G.J., et al. (2009). N. Engl. J. 
Med. 360, 765–773.striction in C. elegans embryonic cells of 
different sizes. They find that cleavage 
rings constrict at a rate that is proportional 
to their initial diameter—a cell with twice 
the diameter constricts twice as fast. As 
a result of this proportionality, the time 
it takes to execute cytokinesis remains 
mostly constant over a wide range of cell 
sizes. Because the rate of ring contrac-
tion is constant once initiated, and larger 
cells have a faster rate of constriction, the 
authors interpret this data as showing 
that cortical rings somehow “memorize” 
their initial circumference and use that 
memory to control the rate of constric-
tion throughout cytokinesis. As the ring 
is an assembly of cytoskeletal proteins, 
the authors further hypothesize that this 
memory is encoded in the structure of the 
initial ring.
How might such a structural memory 
be achieved? One explanation is that the 
number of myosin II molecules recruited 
to the cortical ring is proportional to the 
initial ring diameter. As the ring constricts, 
the motors stay bound to the ring. One 
nd  
tical ring. In this issue, Carvalho 
s that the rate of ring constric-
r, ensuring that the duration of 
